Share on StockTwits

Shares of Horizon Pharma (NASDAQ:HZNP) have been given an average recommendation of “Hold” by the eight brokerages that are covering the company, Analyst Ratings Network.com reports. One investment analyst has rated the stock with a sell recommendation, two have given a hold recommendation and three have given a buy recommendation to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $18.14.

Several analysts have recently commented on the stock. Analysts at Zacks downgraded shares of Horizon Pharma from an “outperform” rating to a “neutral” rating in a research note on Thursday, July 31st. They now have a $11.00 price target on the stock. Separately, analysts at Piper Jaffray downgraded shares of Horizon Pharma from an “overweight” rating to a “neutral” rating in a research note on Tuesday, July 29th. They now have a $9.00 price target on the stock, down previously from $22.00. Finally, analysts at Piper Jaffray initiated coverage on shares of Horizon Pharma in a research note on Monday, July 7th. They set an “overweight” rating on the stock.

Horizon Pharma (NASDAQ:HZNP) opened at 9.38 on Tuesday. Horizon Pharma has a one year low of $2.46 and a one year high of $18.30. The stock’s 50-day moving average is $11.53 and its 200-day moving average is $13.21. The company’s market cap is $701.3 million.

Horizon Pharma (NASDAQ:HZNP) last issued its quarterly earnings data on Thursday, August 7th. The company reported $0.21 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.10 by $0.11. The company had revenue of $66.10 million for the quarter, compared to the consensus estimate of $58.35 million. The company’s quarterly revenue was up 495.5% on a year-over-year basis. Analysts expect that Horizon Pharma will post $0.69 EPS for the current fiscal year.

Horizon Pharma, Inc operates as a biopharmaceutical company. It is focused on developing and commercializing medicines to target unmet therapeutic needs in arthritis, pain and inflammatory diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.